D8 (RBOT)
(Delayed Data from NYSE)
$6.67 USD
-0.75 (-10.11%)
Updated Jun 26, 2024 04:00 PM ET
3-Hold of 5 3
B Value C Growth A Momentum B VGM
Income Statements
Fiscal Year end for Vicarious Surgical Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 0 | 0 | NA |
Cost Of Goods | 0 | 0 | 0 | 0 | NA |
Gross Profit | 0 | 0 | 0 | 0 | NA |
Selling & Adminstrative & Depr. & Amort Expenses | 81 | 80 | 38 | 0 | 0 |
Income After Depreciation & Amortization | -81 | -80 | -38 | 0 | 0 |
Non-Operating Income | 10 | 85 | 3 | 0 | NA |
Interest Expense | 0 | 0 | 0 | 0 | NA |
Pretax Income | -71 | 5 | -35 | 0 | NA |
Income Taxes | 0 | 0 | 0 | 0 | NA |
Minority Interest | 0 | 0 | 0 | 0 | NA |
Investment Gains/Losses | 0 | 0 | 0 | 0 | NA |
Other Income/Charges | 0 | 0 | 0 | 0 | NA |
Income From Cont. Operations | -71 | 5 | -35 | 0 | NA |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | NA |
Net Income (GAAP) | -71 | 5 | -35 | 0 | NA |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -79 | -79 | -38 | 0 | 0 |
Depreciation & Amortization (Cash Flow) | 2 | 1 | 0 | 0 | NA |
Income After Depreciation & Amortization | -81 | -80 | -38 | 0 | 0 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 4.86 | 4.25 | 4.03 | NA | NA |
Diluted EPS Before Non-Recurring Items | -15.62 | -19.52 | -9.91 | NA | NA |
Diluted Net EPS (GAAP) | -14.71 | 1.20 | -10.81 | -0.09 | NA |
Fiscal Year end for Vicarious Surgical Inc falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 16.11 | 15.54 | 21.35 | 21.45 | 22.32 |
Income After SG&A, R&D, and Dept/Amort Expenses | -16.11 | -15.54 | -21.35 | -21.45 | -22.32 |
Non-Operating Income | -0.89 | 2.45 | 5.65 | 6.13 | -4.61 |
Interest Expense | 0.00 | 0.02 | 0.00 | 0.00 | 0.00 |
Pretax Income | -17.00 | -13.11 | -15.70 | -15.33 | -26.92 |
Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -17.00 | -13.11 | -15.70 | -15.33 | -26.92 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -17.00 | -13.11 | -15.70 | -15.33 | -26.92 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | 5.85 | 5.83 | 5.17 | 4.23 | 4.20 |
Diluted EPS Before Non-Recurring Items | -2.70 | -2.10 | -3.60 | -4.80 | -5.11 |
Diluted Net EPS (GAAP) | -3.00 | -1.80 | -3.00 | -3.60 | -6.31 |